Company intelligence / Profile preview

Xianshengweike Biopharmaceutical

Nanjing, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Simcere Vico is a China-based biopharmaceutical company focused on the research, development, and commercialization of innovative vaccines for infectious diseases. As a subsidiary of Simcere Pharmaceutical Group, the company leverages advanced technology platforms, including recombinant protein and mRNA technologies, to address significant public health challenges. Its lead programs include a quadrivalent recombinant influenza vaccine and COVID-19 vaccine candidates. Simcere Vico aims to provide high-quality, effective immunization solutions to the global market through its integrated R&D and manufacturing capabilities.

Therapeutic areas: Infectious Diseases
Modalities: VaccineRecombinant proteinmRNA-based drugs
Industry: Biotech

Partnerships

Simcere Pharmaceutical Group

Beyond the preview

Go deeper on Xianshengweike Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xianshengweike Biopharmaceutical.

Explore the full profile